Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit

September 15, 2021

Company's Scientific Leadership to Highlight Key Findings from Ongoing RAS(ON) Inhibitor Programs

REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate in the upcoming 3rd Annual RAS-Targeted Drug Development Summit being held September 21-23, 2021. Steve Kelsey, M.D., president, research and development, will serve as chairperson for one of the conference's scientific tracks and moderate a panel discussion during the virtual event. In addition, Jan Smith, Ph.D., senior vice president, biology and Bob Nichols, Ph.D., project lead for RMC-6291, the company's development-stage KRAS ^{G12C}(ON) inhibitor, will each deliver a scientific presentation as part of the conference.

Details of Revolution Medicines' participation in the 3 rd Annual RAS-Targeted Drug Development Summit are as follows:

Presentations:

Title:	Targeting KRAS^{G12C}(ON) & Potential Application to Overcoming Drug Resistance in RAS-Addicted Tumors
Presenter:	Bob Nichols, Ph.D., project lead for RMC-6291
Date:	Wednesday, September 22, 2021
Time:	11:55 a.m. Eastern

Title:	Combination Strategies to Defeat RAS-Addicted Cancers
Presenter:	Jan Smith, Ph.D., senior vice president, biology
Date:	Wednesday, September 22, 2021
Time:	2:00 p.m. Eastern

Panel Discussion:

Title:	On the Horizon – Discussing the Post-Approval Landscape for Successful RAS Drugs Beyond AMG510
Moderator:	Steve Kelsey, M.D., president, research and development
Date:	Thursday, September 23, 2021
Time:	4:15 p.m. Eastern

Scientific Track:

Title:	Validating Robust Combination Strategies
Chairperson:	Steve Kelsey, M.D., president, research and development
Date/Time:	Wednesday, September 22, 2021; 11:30 a.m. – 5:00 p.m. Eastern Thursday, September 23, 2021; 11:00 a.m. – 12:30 p.m. Eastern

Additional information on the Digital RAS-Targeted Drug Discovery Summit is available through the conference website at https://ras-drugdevelopment.com/

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.

The company's R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845.

Contacts:

For Investors:
Vida Strategic Partners
Stephanie Diaz
415-675-7401
sdiaz@vidasp.com

For Media:
Vida Strategic Partners
Tim Brons
415-675-7402
tbrons@vidasp.com